Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) EVP Jakob Dupont sold 5,074 shares of Atara Biotherapeutics stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $3.63, for a total value of $18,418.62. Following the transaction, the executive vice president now owns 290,794 shares in the company, valued at $1,055,582.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Atara Biotherapeutics Trading Down 5.0 %
Shares of ATRA stock opened at $3.43 on Tuesday. Atara Biotherapeutics, Inc. has a 12-month low of $2.83 and a 12-month high of $10.01. The stock’s 50-day moving average price is $4.15 and its 200-day moving average price is $4.18. The stock has a market capitalization of $329.04 million, a price-to-earnings ratio of -1.54 and a beta of 0.99.
Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) last issued its earnings results on Wednesday, February 8th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.11). Atara Biotherapeutics had a negative return on equity of 140.05% and a negative net margin of 359.12%. The firm had revenue of $0.22 million during the quarter, compared to the consensus estimate of $60.00 million. As a group, research analysts predict that Atara Biotherapeutics, Inc. will post -2.28 EPS for the current fiscal year.
Institutional Investors Weigh In On Atara Biotherapeutics
Analysts Set New Price Targets
Several equities analysts have recently commented on ATRA shares. HC Wainwright lowered their price objective on Atara Biotherapeutics from $29.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, February 9th. Mizuho restated a “buy” rating and issued a $31.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, February 7th. Finally, EF Hutton Acquisition Co. I restated a “buy” rating and issued a $25.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, February 9th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $19.25.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need.
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- Go Where the Money Is. Here’s 3 Top Bank Dividend Stocks to Buy
- Another Catalyst For Mullen Automotive Stock
- Solar Tech-Services; Nextracker Should Be On Your Radar
- Is American Lithium a Safe Bet as Demand for Lithium Soars
- Highwoods Properties, High-quality Real Estate for a Discount
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.